Headlines

MannKind Corp

Shining on Major News: MannKind Corp. (NASDAQ:MNKD), Exelon Corporation (NYSE:EXC), Coca-Cola Company (NYSE:KO), Seattle Genetics (NASDAQ:SGEN), Yum! Brands, Inc. (NYSE:YUM)

Chris Lewis02 mins

On August 11,2014 MannKind Corp. (NASDAQ:MNKD) reported financial results for the second quarter ended June 30, 2014. For the second quarter of 2014, total operating expenses were $69.8 million, compared to $41.6 million for the second quarter of 2013, an increase of $28.2 million, largely due to an increase in non-cash stock compensation expense of…

Read More

Hot Stocks : MannKind Corp. (NASDAQ:MNKD), NCR Corp. (NYSE:NCR), PriceSmart Inc. (NASDAQ:PSMT), Alliance Fiber Optic Products Inc. (NASDAQ:AFOP), NVR, Inc. (NYSE:NVR)

Adam Keintzel02 mins

MannKind Corporation (NASDAQ:MNKD) signed a $925 million worldwide licensing agreement with Sanofi SA (ADR) (NYSE:SNY) (EPA:SAN) on August 11. The French drugmaker already has five principal products in diabetes. However, its top-selling diabetes drug Lantus will lose patent protection next year. Lantus is sold in more than 120 countries, generating $7.6 billion in annual revenue….

Read More

Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Mark Doerr02 mins

Amgen Inc. (NASDAQ:AMGN) carries a Zacks Rank #1 (Strong Buy). Amgen, Inc. (NASDAQ:AMGN) stock performance was -1.90% in last session and finished the day at $111.94. Traded volume was 7.26million shares in the last session and the average volume of the stock remained 3.63million shares. The beta of the stock remained 0.51. Amgen, Inc. (NASDAQ:AMGN)…

Read More
Gilead Sciences GILD NASDAQ:GILD

Biotech Losers: MannKind Corporation (NASDAQ:MNKD), Rexahn Pharmaceuticals (NYSEMKT:RNN), ZIOPHARM Oncology (NASDAQ:ZIOP), Seattle Genetics (NASDAQ:SGEN)

Kristen Barton02 mins

MannKind Corporation (NASDAQ:MNKD) announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) date for AFREZZA(R) by three months to July 15, 2014 in order to provide time for a full review of information submitted by MannKind in response to the FDA’s requests.MannKind Corporation (NASDAQ:MNKD) stock performance…

Read More

Healthcare Active Runners: Gilead Sciences (NASDAQ:GILD), Pfizer Inc. (NYSE:PFE), Merck & Co. (NYSE:MRK), MannKind Corporation (NASDAQ:MNKD)

Colin Pettis12 mins

Gilead Sciences, Inc. (NASDAQ:GILD) announced data from two Phase 2 studies and a compassionate access study in which a regimen containing once-daily Sovaldi(R) (sofosbuvir) 400 mg was administered for the treatment of chronic hepatitis C virus (HCV) infection in patients with advanced liver disease. Gilead Sciences, Inc. (NASDAQ:GILD) stock performance was -7.32% in last session…

Read More

Healthcare active runners: Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK), Pfizer Inc. (NYSE:PFE), MannKind Corporation (NASDAQ:MNKD)

Jason Knox02 mins

On Monday, Johnson & Johnson (NYSE:JNJ) announced that it accepted the binding offer from The Carlyle Group (NASDAQ:CG), which was received and announced on January 16, 2014, to acquire its Ortho-Clinical Diagnostics business for approximately $4 Billion, subject to customary adjustments. Johnson & Johnson (NYSE:JNJ) stock performance was 0.16% in last session and finished the…

Read More
Home